The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease

The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease

Abstract Background People with chronic kidney disease (CKD) are at an increased risk of developing hyperkalaemia due to their declining kidney function. In addition, these patients are often required to reduce or discontinue guideline-recommended renin-angiotensin-aldosterone system inhibitor (RAAS...

Full description

Bibliographic Details
Main Authors: Marc Evans, Eirini Palaka, Hans Furuland, Hayley Bennett, Cecilia Linde, Lei Qin, Phil McEwan, Ameet Bakhai
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Nephrology
Subjects:
Chronic kidney disease
Potassium, Hyperkalaemia
Renin-angiotensin-aldosterone system inhibitor
Economic modelling
Online Access:http://link.springer.com/article/10.1186/s12882-019-1228-y

Internet

http://link.springer.com/article/10.1186/s12882-019-1228-y

Similar Items